Marc Frahm

Stock Analyst at TD Cowen

(0.19)

# 4,446

Out of 5,172 analysts

16

Total ratings

15.38%

Success rate

-19.57%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Marc Frahm

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NKTR Nektar Therapeutics	Initiates: Buy	n/a	$72.22	-	1	Mar 17, 2026
	INCY Incyte	Maintains: Buy	$101 → $128	$90.78	+41.00%	4	Jan 13, 2026
	SANA Sana Biotechnology	Upgrades: Buy	n/a	$3.11	-	2	Jan 8, 2025
	TBPH Theravance Biopharma	Maintains: Hold	$10 → $9	$14.33	-37.19%	3	Aug 6, 2024
	CGEM Cullinan Therapeutics	Initiates: Outperform	n/a	$12.74	-	1	Jun 15, 2023
	XLO Xilio Therapeutics	Initiates: Outperform	n/a	$7.86	-	1	Nov 16, 2021
	NUVL Nuvalent	Initiates: Outperform	n/a	$94.77	-	1	Aug 23, 2021
	JANX Janux Therapeutics	Initiates: Outperform	n/a	$14.06	-	1	Jul 6, 2021
	DAWN Day One Biopharmaceuticals	Initiates: Outperform	n/a	$21.44	-	1	Jun 21, 2021
	BDTX Black Diamond Therapeutics	Initiates: Outperform	n/a	$2.11	-	1	Feb 24, 2020

Nektar Therapeutics

Mar 17, 2026

Initiates: Buy

Price Target: n/a

Current: $72.22

Upside: -

Incyte

Jan 13, 2026

Maintains: Buy

Price Target: $101 → $128

Current: $90.78

Upside: +41.00%

Sana Biotechnology

Jan 8, 2025

Upgrades: Buy

Price Target: n/a

Current: $3.11

Upside: -

Theravance Biopharma

Aug 6, 2024

Maintains: Hold

Price Target: $10 → $9

Current: $14.33

Upside: -37.19%

Cullinan Therapeutics

Jun 15, 2023

Initiates: Outperform

Price Target: n/a

Current: $12.74

Upside: -

Xilio Therapeutics

Nov 16, 2021

Initiates: Outperform

Price Target: n/a

Current: $7.86

Upside: -

Nuvalent

Aug 23, 2021

Initiates: Outperform

Price Target: n/a

Current: $94.77

Upside: -

Janux Therapeutics

Jul 6, 2021

Initiates: Outperform

Price Target: n/a

Current: $14.06

Upside: -

Day One Biopharmaceuticals

Jun 21, 2021

Initiates: Outperform

Price Target: n/a

Current: $21.44

Upside: -

Black Diamond Therapeutics

Feb 24, 2020

Initiates: Outperform

Price Target: n/a

Current: $2.11

Upside: -